These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 18358758)

  • 21. Reported mutations in GIGYF2 are not a common cause of Parkinson's disease.
    Vilariño-Güell C; Ross OA; Soto AI; Farrer MJ; Haugarvoll K; Aasly JO; Uitti RJ; Wszolek ZK
    Mov Disord; 2009 Mar; 24(4):619-20. PubMed ID: 19133664
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinson's disease.
    Ng AS; Tan J; Ng E; Tay KY; Au WL; Tan LC; Tan EK
    J Neurol Neurosurg Psychiatry; 2023 Mar; 94(3):250-251. PubMed ID: 36171102
    [No Abstract]   [Full Text] [Related]  

  • 23. Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Schneider SA; Alcalay RN
    Mov Disord; 2020 Jul; 35(7):1134-1135. PubMed ID: 32379375
    [No Abstract]   [Full Text] [Related]  

  • 24. The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease.
    Gutti U; Fung HC; Hruska KS; Lamarca ME; Chen CM; Wu YR; Sidransky E
    Arch Neurol; 2008 Jun; 65(6):850-1; author reply 851. PubMed ID: 18541817
    [No Abstract]   [Full Text] [Related]  

  • 25. Penetrance of PD in Glucocerebrosidase Gene Mutation Carriers.
    Sidransky E; Hart PS
    Neurology; 2012 Jul; 79(1):106-7. PubMed ID: 22753448
    [No Abstract]   [Full Text] [Related]  

  • 26. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
    Paus S; Gadow F; Knapp M; Klein C; Klockgether T; Wüllner U
    Mov Disord; 2009 May; 24(7):1080-4. PubMed ID: 19353703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.
    Emre S; Gürakan F; Yüce A; Rolf A; Scott R; Ozen H
    Eur J Med Genet; 2008; 51(4):315-21. PubMed ID: 18586596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examination of the MSX1 gene in patients with Parkinson's disease.
    Deng H; Zhu SH; Le WD; Yang HR; Lv HW; Xu HB; Xie WJ; Jankovic J
    Acta Neurol Scand; 2009 Dec; 120(6):442-4. PubMed ID: 19922584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2022 Mar; 37(3):651-652. PubMed ID: 35064687
    [No Abstract]   [Full Text] [Related]  

  • 30. Parkinson's disease secondary to 2 mutations of genes involved in lysosomal protein degradation.
    Fernández-Pajarín G; Sesar A; Ares-Pensado B; Castro A
    Neurologia (Engl Ed); 2020 Oct; 35(8):611-612. PubMed ID: 31771779
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication.
    Orimo S; Uchihara T; Nakamura A; Mori F; Ikeuchi T; Onodera O; Nishizawa M; Ishikawa A; Kakita A; Wakabayashi K; Takahashi H
    Acta Neuropathol; 2008 Nov; 116(5):575-7. PubMed ID: 18751989
    [No Abstract]   [Full Text] [Related]  

  • 32. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies.
    Parnetti L; Balducci C; Pierguidi L; De Carlo C; Peducci M; D'Amore C; Padiglioni C; Mastrocola S; Persichetti E; Paciotti S; Bellomo G; Tambasco N; Rossi A; Beccari T; Calabresi P
    Neurobiol Dis; 2009 Jun; 34(3):484-6. PubMed ID: 19303930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocerebrosidase mutations: tipping point toward Parkinson disease and dementia?
    Klein C; Krainc D
    JAMA Neurol; 2013 Jun; 70(6):686-8. PubMed ID: 23588619
    [No Abstract]   [Full Text] [Related]  

  • 34. Gaucher disease: report of de novo GBA mutation in a Spanish family.
    Alfonso P; Pocovi M; Giraldo P
    Blood Cells Mol Dis; 2008; 40(3):444-5. PubMed ID: 18313951
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis?
    Albin RL; Dauer WT
    Neurology; 2012 Jul; 79(3):202-3. PubMed ID: 22722622
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased risk for heterozygotes in recessive Parkinson disease.
    Beffert U; Rosenberg RN
    Arch Neurol; 2006 Jun; 63(6):807-8. PubMed ID: 16769859
    [No Abstract]   [Full Text] [Related]  

  • 37. Surgicogenomics in GBA1-related Parkinson disease: Is the glass half full or half empty?
    Salles PA; Fernández HH; Mata IF
    Parkinsonism Relat Disord; 2024 Jul; 124():106981. PubMed ID: 38714481
    [No Abstract]   [Full Text] [Related]  

  • 38. Association analysis of PSAP variants in Parkinson's disease patients.
    Chao YX; Lee B; Ng EY; Lian MM; Chew EGY; Tandiono M; Li Z; Khor CC; Kumar P; Tan LCS; Foo JN; Tan EK
    Brain; 2021 Feb; 144(1):e9. PubMed ID: 33221828
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of full sequencing GBA1 studies for patients with Parkinson's disease in Latin America.
    Santos-Lobato BL; Schumacher-Schuh AF; Mata IF
    NPJ Parkinsons Dis; 2022 Aug; 8(1):101. PubMed ID: 35941142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GBA-Associated Parkinson's Disease and Other Synucleinopathies.
    Gan-Or Z; Liong C; Alcalay RN
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):44. PubMed ID: 29884970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.